Background. Full, as compared with partial, correction of anaemia did not reduce the mortality risk in patients with chronic kidney disease (CKD), although the underlying mechanisms are unknown. Since CKD is a high-risk population for cardiovascular disease (CVD), we tested a hypothesis that the presence of atherosclerosis affects the relationship between anaemia and mortality risk. Methods. We performed a single-centre 10-year follow-up study with an observational cohort of 505 haemodialysis patients to analyse the relationship between haematocrit and all-cause mortality. Baseline haematocrit levels did not differ between the 153 patients with CVD and the 352 patients without CVD. Results. During the follow-up, 268 patients died. Both Kaplan-Meier and univariate Cox analyses showed that higher haematocrit levels were a significant predictor of lower risk of death in the CVD (−) group, whereas haematocrit did not predict death in the CVD (+) group. In multivariate Cox analyses, the inverse relationship between haematocrit and mortality in the CVD (−) group remained significant and independent of 14 covariates including the use of erythropoietin. In contrast, using the same Cox models, the CVD (+) group did not show such a beneficial effect of higher haematocrit. Similar observations were made when the subjects were divided based on carotid artery intima-media thickness instead of the presence of CVD. Conclusions. These results support the hypothesis that the presence of atherosclerosis alters the relationship between anaemia and mortality risk in haemodialysis patients.
Introduction
Death risk is substantially elevated in end-stage renal disease, and the cardiovascular disease is the leading cause of death in the haemodialysis population [1] . Recent studies revealed that risk of occurrence of cardiovascular disease (CVD) events [2] and risk of death after myocardial infarction [3] are both increased in a stepwise manner as the stage of chronic kidney disease (CKD) is advanced before renal replacement therapies are initiated. Arterial wall thickness [4] and stiffness [5, 6] are increased in predialysis patients with CKD as well as in patients on maintenance haemodialysis [7] [8] [9] . These vascular wall changes are predictors for mortality in the haemodialysis population [10, 11] .
In addition to these atherosclerotic vascular changes, anaemia is associated with poor survival in CKD patients. Anaemia is associated with impairment in quality of life [12] , physical performance [13] and survival in haemodialysis patients [14, 15] . Partial correction of anaemia with human recombinant erythropoietin (rHuEPO) was reported to improve physical performance [16] and left ventricular hypertrophy (LVH) [17] in haemodialysis patients, and it was also reported to retard loss of renal function in predialysis patients with chronic renal failure [18] . Clinical practice guidelines from Europe [19] and the United States [20] have recommended to achieve a haemoglobin level >11 g/dL (haematocrit higher than 33%).
Surprisingly, however, normalization of the haematocrit or haemoglobin level is not necessarily better for survival, LVH and renal function as shown in randomized controlled trials in patients with stage 5 CKD on dialysis [21, 22] and in patients with stage 3-4 CKD [23, 24] . A recent metaanalysis of these studies [25] showed that full, as compared with partial, correction of haemoglobin and haematocrit levels is associated with increased risk of all-cause mortality by 17%. The US Food and Drug Administration (FDA) advised physicians to monitor patients' haemoglobin levels to ensure they do not exceed 12 g/dL [26] . The National Kidney Foundation has also updated the target haemoglobin levels generally to be in the range of 11.0-12.0 g/dL in the latest version of the KDOQI guidelines [27] .
So far, however, it is unknown whether all haemodialysis patients benefit from the recommended level of anaemia correction. Lower haematocrit levels might be better for some specific groups of haemodialysis patients. A higher haematocrit directly increases oxygen content of blood on one hand, but it increases blood viscosity and reduces blood flow volume on the other hand. Accordingly, there is an optimal haematocrit level in view of oxygen delivery to tissue [28] . Since blood flow volume is affected not only by blood viscosity but blood vessel as well, it is possible that the optimal haematocrit levels for survival are different in the absence and the presence of atherosclerosis.
In the present study using a historical cohort of haemodialysis patients, we tested the above hypothesis by examining the association between haematocrit levels and mortality risk in the two groups of haemodialysis patients with and without history of CVD at baseline. Similar analyses were also performed based on carotid artery intimamedia thickness (CA-IMT) at baseline, rather than history of CVD.
Methods

Study design and subjects
This is a observational cohort study of patients on maintenance haemodialysis to analyse predictors of mortality. Baseline studies were performed in October 1996. Information was collected for pre-existing CVD, medications, body weight, height, blood pressure, haematocrit, blood chemistry and other clinical parameters. In 423 patients who agreed to perform carotid arterial echography, carotid artery intima-media thickness was also measured in the period between August and October 1996. The cohort was followed up until October 2006. They had been treated by regular haemodialysis for >1 month at Kidney Center, Shirasagi Hospital, Osaka, Japan. The 505 subjects were recruited from 508 total outpatients on haemodialysis excluding 3 with advanced malignancy at baseline. Mean (±SD) age at entry was 60.2 ± 12.5 years, and 61% of them were male. Mean Kt/V was 1.14 ± 0.23. Median (range) duration of haemodialysis before inclusion was 55 (1-312) months. They received 3-5 h of haemodialysis, three times a week, using standard bicarbonate dialysate. This study was approved by the ethics committee of the hospital, and all the subjects gave informed consent to participate in the study.
Pre-existing CVD at baseline
Pre-existence of CVD was evaluated by clinical information regarding coronary, cerebral and peripheral artery diseases and aortic aneurysm. Coronary artery disease was diagnosed when a subject had one or more of the following criteria: (1) past history of percutaneous coronary intervention or coronary artery bypass grafting, (2) presence of significant stenosis by coronary angiography, (3) presence of ST-T abnormalities on electrocardiogram associating typical symptoms attributable to angina pectoris and (4) use of one or more medications for coronary ischaemia. Seventy-seven patients were diagnosed to have coronary artery disease. Cerebrovascular disease was diagnosed by past history that had been confirmed by positive findings of infarction or bleeding by X-ray computed tomography or magnetic resonance imaging. Seventy-two patients had such past history. Peripheral artery disease was diagnosed in seventeen patients whose legs had been amputated due to angiographically demonstrated leg ischaemia. Diagnosis of aortic aneurysm was made by X-ray computed tomography in six patients. At baseline, 153 patients had one or more of the above cardiovascular complications.
Body weight and blood pressure measurements
Body weight denotes 'dry weight' and body mass index (BMI) was calculated by dividing dry weight (kg) by squared height (m 2 ). Blood pressure was measured with a standard mercury sphygmomanometer and cuffs adapted to arm circumference, after the subject had rested in the supine position for at least 5 min. The systolic and diastolic blood pressure levels were taken as the points of appearance and disappearance of Korotkoff sounds, respectively. The average of three measurements was used for analysis.
Blood sampling and assays
Blood was taken just before the start of the first dialysis session of the week in a supine position, and drawn into vacuum plastic tubes. Whole blood was used for haematocrit and serum for other biochemical assays. These assays were performed without delay using an automated analyser. Intact parathyroid hormone (PTH) was determined by a two-site immunoradiometric assay (Allegro Intact PTH, Nichols Institute Diagnostics, CA, USA) [29] .
Carotid artery intima-media thickness (CA-IMT)
CA-IMT was measured by high-resolution real-time ultrasonography as we previously described [7, 30, 31] . In this study, we used an ultrasound apparatus with a 7.5 MHz linear scanner (Aloka Model SSD 610 CL, Aloka Co. Ltd, Tokyo, Japan) [32] . The maximum value of the intimamedia complex at the most advanced carotid lesion was used for analysis. The coefficient of variation (CV) of CA-IMT by this method was 3.3% for haemodialysis patients [7] . In our previous study [33] , 0.94 mm was the 95th percentile level of CA-IMT among 446 healthy Japanese people.
Outcome data collection
The haemodialysis cohort was followed up to the end of September 2006 with a mean and a median (range) followup period of 82 and 93 (1-120) months, respectively. At The table gives percentage, mean ± SD or median (range). * P < 0.05, * * P < 0.01, * * * P < 0.001 versus CVD (−) group by the χ 2 test, ANOVA or Mann-Whitney U-test. Abbreviations: CVD, cardiovascular disease; HD, haemodialysis; DM, diabetes mellitus; BP, blood pressure; HDL-C, high density lipoprotein cholesterol; Non-HDL-C, non-high-density lipoprotein cholesterol; PTH, parathyroid hormone; rHuEPO, recombinant human erythropoietin; IV-Fe, intravenous iron injection; CaCO 3 , calcium carbonate; ACE-I, angiotensin-converting enzyme inhibitor.
the end of the follow-up, 217 patients were confirmed to be alive on haemodialysis and 269 patients to be dead. The date and cause of death were obtained by reviewing the hospital record forms. The remaining 19 out of the 505 total patients were censored during the followup, either at the time of renal transplantation (n = 5) or at the time of moving away from Shirasagi Hospital (n = 14).
Statistical analysis
Continuous variables were summarized as mean ± SD. Median (range) was given for duration of haemodialysis, C-reactive protein and intact PTH because of their skewed distribution. Proportion was given in percentage. Differences of mean, median and percentage between two groups were evaluated by analysis of variance, MannWhitney U-test or χ 2 test, respectively. Survival curves were constructed by the Kaplan-Meier method and evaluated by the log-rank test. Prognostic variables for survival were examined using univariate Cox proportional hazards regression models, and independent predictors of death were determined by using multivariate Cox analyses. P-values <0.05 were considered significant. All these analyses were performed using statistical software (StatView 5, SAS Institute Inc., Cary, NC, USA) for Windows personal computers.
Results
Baseline characteristics of the cohort
Baseline studies were performed in October 1996. Table 1 summarizes the baseline characteristics of the cohort. At baseline, 153 out of the total 505 subjects had pre-existing CVD as defined in the Methods section.
Outcomes and death rates of the cohort
For the total cohort, 268 deaths occurred during the mean follow-up of 82 months, and the crude annual mortality rate was 7.8%. This figure was lower than the mortality rate of 9.4% for the entire Japanese dialysis patients in 1996 reported by the Japanese Society for Dialysis Therapy (JSDT) but higher than the mortality rate of 6.4% for the Japanese dialysis patients participating in the DOPPS [34] .
The causes of 268 deaths included 142 fatal cardiovascular events: coronary heart disease (n = 30), cerebrovascular disease (n = 36), congestive heart failure (n = 39), rupture of aortic aneurysm (n = 5), ischaemic colitis (n = 8) and sudden death (n = 24). Sudden death was defined as a witnessed death that occurred within 1 h after the onset of acute symptoms, with no evidence of accident or violence. The 126 fatal non-cardiovascular causes were infectious disease (n = 40), malignancy (n = 22), hepatic failure (n = 12), respiratory disease (n = 8), gastrointestinal disease (n = 4), bleeding (n = 4), accident (n = 4), declining of dialysis (n = 2), suicide (n = 1) and others (n = 29).
In the CVD (−) group, 139 deaths were recorded during the mean follow-up of 92 months, and the crude annual mortality rate was 5.2%. The causes of death were coronary heart disease (n = 10), cerebrovascular disease (n = 17), congestive heart failure (n = 9), rupture of aortic aneurysm (n = 1), ischaemic colitis (n = 6), sudden death (n = 15), infectious disease (n = 21), malignancy (n = 17), hepatic failure (n = 8), respiratory disease (n = 5), gastrointestinal disease (n = 3), bleeding (n = 3), accident (n = 3), declining of dialysis (n = 2) and others (n = 19).
In the CVD (+) group, 129 deaths occurred during the mean follow-up period of 59 months, and the crude annual mortality rate was 17.1%. The causes of death were coronary heart disease (n = 20), cerebrovascular disease (n = 19), congestive heart failure (n = 30), rupture of aortic aneurysm (n = 4), ischaemic colitis (n = 2), sudden death (n = 9), infectious disease (n = 19), malignancy (n = 5), hepatic failure (n = 4), respiratory disease (n = 3), gastrointestinal disease (n = 1), bleeding (n = 1), accident (n = 1), suicide (n = 1) and others (n = 10).
Mortality rates in relation to haematocrit levels in the CVD (−) and CVD (+) groups
We divided the total cohort into four categories by haematocrit levels at an interval of 3%, namely <27%, 27-30%, 30-33% and 33% or higher. The distribution of subjects among the four haematocrit categories was 99, 148, 60, 45 for the CVD (−) group and 48, 62, 19, 24 for the CVD (+) group. Then, we analysed the association between the haematocrit and mortality risk in the CVD (−) and the CVD (+) groups, respectively, by the Kaplan-Meier method (Figure 1 ). In the CVD (−) group, mortality rate was significantly lower in the higher levels of haematocrit. Univariate Cox analysis indicated that an increase in haematocrit (%) by 1 point was associated with a decrease in mortality by 8.1% (Table 2 ). In contrast, such an inverse relationship was not significant in the CVD (+) group.
Other univariate predictors of mortality
Other predictors of mortality were examined by univariate Cox analysis (Table 2 ). In the total cohort, significant predictors other than a lower haematocrit were, a higher age, a shorter duration of dialysis, the pre-existence of CVD, the presence of diabetes mellitus, a lower BMI, a lower serum albumin, a higher C-reactive protein (CRP), a lower high-density lipoprotein (HDL) cholesterol, a lower serum phosphorus and a lower serum calcium. Sex was at a borderline significance (P = 0.075), but intact PTH was not significant in univariate Cox analysis.
In the CVD (−) group, significant predictors other than a lower haematocrit were a higher age, the presence of diabetes mellitus, a lower serum albumin, a higher CRP and a lower HDL cholesterol. Other variables were not significant in univariate Cox analysis.
In the CVD (+) group, significant predictors were a higher age, the presence of diabetes mellitus, a lower serum albumin and a higher CRP. Other variables were not significant in univariate Cox analysis.
Multivariate Cox analysis in the CVD (−) and CVD (+) groups
We examined whether the inverse association between haematocrit and mortality risk in the CVD (−) group was independent of other confounding variables using multivariate Cox models (Table 3) . When unadjusted for other variables, a higher haematocrit level was significantly associated with a lower risk of death (Model 1). The inverse association remained significant after adjustment for age, sex, duration of dialysis, systolic blood pressure and diabetes mellitus (Model 2). Further adjustment for CRP, serum albumin and BMI (Model 3), plus calcium and phosphorus (Model 4), plus HDL cholesterol (Model 5) did not alter the association between haematocrit and mortality. The inverse association between haematocrit and mortality risk in the CVD (−) group remained significant even after further adjustment for medications such as use of erythropoietin (Model 6), use of calcium carbonate and use of anti-hypertensive medications (Model 7).
By contrast, in the CVD (+) group, the association between haematocrit and mortality risk was consistently insignificant when adjusted for these covariates using the same models.
Analyses based on CA-IMT instead of history of CVD
To evaluate whether atherosclerotic vascular changes explain the distinct patterns of mortality in relation to haematocrit in the CVD (−) and CVD (+) groups, we analysed the data based on CA-IMT rather than history of CVD. Data of carotid artery ultrasound examinations were available in 423 out of the 505 total subjects. The 423 patients were divided into two groups having lower CA-IMT (<0.94 mm, n = 279) and higher CA-IMT (>0.94 mm, n = 144) values. The cut-off level was the 95th percentile level of 446 healthy Japanese subjects enrolled in our previous study [33] . As compared with the total cohort of the 505 patients, the 423 patients were not different in age 
The table gives hazards ratios (95% confidence intervals) with levels of significance. Because the distributions of C-reactive protein and intact PTH were highly skewed, these data were treated as categorical data. The cut-off levels were 0.2 mg/dL for C-reactive protein and 72 pg/mL for intact PTH based on the corresponding median values in the total subjects. Abbreviations are the same as those in Table 1 . The table gives hazards ratios (95% confidence intervals) and P-values for mortality per 1% increase in haematocrit in the CVD (−) group and the CVD (+) group. Model 7 includes haematocirt and other 14 covariates. Abbreviations: CVD, cardiovascular disease; HD, haemodialysis; SBP, systolic blood pressure; CRP, C-reactive protein; BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; rHuEPO, recombinant human erythropoietin; CaCO 3 , calcium carbonate. The table gives hazards ratios (95% confidence intervals) and P-values for mortality per 1% increase in haematocrit in the two groups based on the initial CA-IMT values. Model 7 includes haematocirt and other 14 covariates. Abbreviations are the same as those for Table 3 .
(60.1 ± 12.6 years), sex (61% male), haematocrit (28.8 ± 3.7%) or the crude annual mortality rate (7.8%). The numbers of deaths, mean follow-up periods and crude annual mortality rates for the lower versus the higher CA-IMT groups were 110 versus 113 deaths, 91.5 versus 60.0 months and 5.2% versus 15.7%, respectively. Table 4 gives Cox analyses performed to examine the association between haematocrit and mortality in the lower and higher CA-IMT groups separately using the same models as shown in Table 3 . The lower CA-IMT group repeatedly showed significant and inverse association of haematocrit with mortality risk in these models, although it was at a borderline significance (P = 0.076) in Model 7 in which full adjustment was made for the 14 covariates. In contrast, the higher CA-IMT group consistently showed no significant association of haematocrit with mortality risk.
Discussion
We examined whether the presence of atherosclerosis affects the association between haematocrit and mortality risk in this observational cohort study of haemodialysis patients. The patients without CVD showed an inverse association between haematocrit and mortality risk, whereas those with CVD did not show such a clear association. The distinct pattern of the haematocrit-mortality relationship between the patient groups with and without CVD was consistently found even after multivariate adjustment. Similarly, the patients having a lower CA-IMT showed an inverse association between haematocrit and mortality risk, whereas those having a higher CA-IMT did not show such an association. These data indicate that atherosclerosis is an important factor affecting the risk of death due to anaemia in haemodialysis patients.
The present study showed that a higher haematocrit level was significantly associated with a lower risk of mortality in haemodialysis patients without atherosclerosis, but that haematocrit was not significantly associated with mortality risk in the subgroup of haemodialysis patients with atherosclerosis. Although the precise mechanism is unknown, there are several explanations for this observation. First, although a higher haematocrit directly increases oxygen content of blood, it also increases blood viscosity and reduces flow volume. Therefore, oxygen delivery to vital organs may be decreased over a certain level of haematocrit as reported by Hirakata et al. [28] . Since blood flow volume is affected not only by blood viscosity but also by blood vessel properties, we speculate that such an adverse rheological impact of a higher haematocrit on tissue oxygen delivery is greater in subjects with atherosclerotic vascular changes, resulting in worse outcomes. In support of our speculation, Ruschitzka et al. [35] reported survival of transgenic mice overexpressing human erythropoietin that developed polycythaemia with haematocrit of 80%. The survival of the polycythaemic mice was not shorter due to marked increase in endothelial nitric oxide (NO) synthase, NO-mediated endothelium-dependent relaxation, and circulating and vascular tissue NO levels. Inhibition of NO synthesis by treatment with L-NAME resulted in vasoconstriction of peripheral resistance vessels, hypertension and death of the polycythaemic mice in a few days, whereas wild-type siblings did not show increased mortality despite hypertension following the same treatment. Clinically, endothelial function is impaired in patients with CVD [36] , correlating closely with CA-IMT [37] . Thus, the difference in the haematocrit-mortality relationship between the CVD (−) and CVD (+) groups could be attributable at least partly to the presence of atherosclerotic vascular changes that reflect the impaired NO system in the CVD (+) group.
Second, because anaemia correction improves vitality and physical activity, the risk of cardiac events may be raised at higher haematocrit levels if the patient has advanced atherosclerosis. Such an increased risk is less likely to occur in those without atherosclerosis. Also, improved activity may increase intake of sodium and potassium, resulting in hypertension, cardiac accidents and worse outcomes. Third, the means to achieve a higher target of haematocrit may have deleterious effects. Iron is a highly reactive metal that may increase oxidative stress if it is excessively accumulated. In dialysis patients, the regulation of intracellular iron storage is impaired and its levels in polymorphonuclear leukocytes are increased [38] . A high serum ferritin level is known as a predictor of poor survival of haemodialysis patients [39] . In addition, the use of rHuEPO may increase blood pressure [40] which could have an additional adverse impact on survival. However, we failed to show the association of the use of rHuEPO or intravenous iron injections with mortality risk in the present cohort.
Our data support the current concept that we should aim at a higher haemoglobin/haematocrit level within the range of 'partial' correction of anaemia. In haemodialysis patients without CVD, a higher haematocrit level was associated with better survival. Although a higher haematocrit was not associated with better survival in those with CVD, better quality of life is expected by anaemia correction [12] . Thus, haemodialysis patients would receive overall benefit from partial anaemia correction regardless of the presence of CVD.
There are limitations in this study. First, because of the observational nature of this cohort study, the associations do not necessarily indicate causality. Therefore, although the results of this study are of clinical interest, randomized controlled trials are needed to prove the hypothesis. Second, our study does not answer whether haematocrit levels higher than the recommended target are associated with worse outcome in patients with atherosclerosis. Such an analysis was difficult because the haematocrit levels were relatively low. Only 69 patients (13.6%) of the cohort exceeded a the haematocrit of 33%, the upper limit of the target range recommended by the Japanese Society for Dialysis Therapy [41] , and 29 patients (5.7%) exceeded a the haematocrit of 36% that corresponds to the upper limit of the recommended haemoglobin level (12 g/dL) by the latest FDA Sounds Alert [26] and the KDOQI guidelines [27] . Third, although the cohort of this study included most of the haemodialysis patients of the hospital, there might have been some selection bias. This was a single-centre study of prevalent dialysis patients in an urban area of Osaka, Japan. Thus, generalizability should be carefully considered with regard to ethnic groups, geographic areas and prevalent versus incident dialysis patients. Fourth, we calculated the mortality risk based on the one-point measurements of haematocrit at the start of observation, not averaged values during the followup. Therefore, we could only show the very remote effect on mortality during a 10-year follow-up. Time-varying analysis based on sequential measurements during the follow-up may give more direct association between haematocrit and outcomes. Fifth, because many haemodialysis patients are thought to have asymptomatic coronary artery disease, such patients with advanced atherosclerosis might have been excluded from the CVD (+) group, and the association among anaemia, atherosclerosis and mortality risk might have been underestimated. This is the reason why we performed additional analysis based on CA-IMT. However, since CA-IMT could not perfectly predict asymptomatic coronary lesions, studies with coronary angiography may provide more impressive data than the current study.
In conclusion, the present observational study indicates that higher as compared to lower achieved haematocrit levels are only associated with better prognosis in patients without evidence for advanced atherosclerosis. This could imply that optimal target haemoglobin levels differ depending on cardiovascular comorbidity.
